These findings are supported by reports in the literature that collectively established the anti-EMT role of FOXO4 in a variety of cancer types, such as gastric cancer (Su et al., 2014) and non-small-cell cancer (Xu et al., 2014; Li et al., 2016). Here, FOXO4 is linked to gastric cancer.